

Vigmed Holding AB presents interim report January – June

Vigmed Holding AB presents today their interim report for January 1–June 30, 2015.

During the first six months, sales to distributors in Germany, France, Italy, Switzerland, Austria, Belgium and Australia/New Zealand were initiated.

Vigmed Holding AB was approved for listing on the segment First North Premier. First day of trade was April 28, 2015.

- Net Sales for the first six months amounted to SEK 2.0 million (0.2 SEK in the first six months 2014).
- Operating result in the first six months for the Group amounted to SEK -17.7 million (SEK -13.5 million).
- Net income per weighted number of shares for the first six months amounted to SEK -0.37 (SEK -0.36).
- Cash flow from operating activities during the first six months amounted to SEK -26.8 million (SEK -11.0 million). Cash flow from operating activities is mainly driven by the negative result (SEK -16.0 million) and purchase of inventory of finished goods for SEK -5.4 million.

After the reporting period Vigmed has hired Donya Gholamifar as CFO for Vigmed Holding AB and Vigmed AB. She will work on a part-time basis as per October 1, 2015, to be engaged full time from the end of the year. Donya is a chartered accountant and senior manager at PwC, where she has worked with the audit of Vigmed since 2013. She replaces Mette Gross, who has been interim CFO since 2012.

For further
information contact:

Chairman of the
board
Lennart Holm
+46 70 630 8562 or

CEO
Finn Ketler
+46 42 600 5311

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has 20 employees. Vigmed's share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 600 shareholders. Remium Nordic AB is the Company's Certified Advisor. Additional information about the company can be found on Vigmed's website: www.vigmed.com/investor